Compare Charles River Laboratories Intl. Inc (CRL) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Oracle Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while Oracle Corporation trades at $132.95 (market cap $368.53B). The key difference: Oracle Corporation is far larger — about 33.1× Charles River Laboratories Intl. Inc's market cap, and Oracle Corporation pays a 1.56% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ORCL | |
|---|---|---|
Market Cap | $11.14B | $368.53B |
Sector | Health | Technology |
52-Week High | $233.60 | $328.33 |
52-Week Low | $145.57 | $127.96 |
Enterprise Value | $14.00B | $497.78B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Oracle (ORCL) trades at $131.86, down 6.27% in the last 24 hours, amid a bearish technical signal but strong fundamental performance. The company reported revenue of $57.40B in 2025 with a net income margin of 25.37%, and has beaten earnings estimates for the last three quarters. Recent news highlights Oracle's AI infrastructure growth and a pending Q2 2026 earnings report on June 10, 2026.
The outlook for Oracle is positive due to robust earnings growth and AI-driven opportunities, though risks include high debt levels and competitive pressures. Analysts maintain a bullish consensus with a $259 price target, suggesting significant upside from the current price if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
